Prevalence of antiretroviral drug resistance in treated HIV-1 infected patients: Under the initiative of access to the NNRTI-based regimen in Thailand

Journal of Chemotherapy

Volumn 19, Issue 5, 2007, Pages 528-535

  Sukasem, Chonlaphat ^a,b   Churdboonchart, V ^a   Chasombat, S ^c   Kohreanudom, S ^c   Watitpun, Chotip ^b   Piroj, Wantanich ^b   Tiensuwan, Montip ^a   Chantratita, Wasun ^b  

^a Mahidol University ^*  (Thailand)

^b MAHIDOL UNIVERSITY   (Thailand)

^c MINISTRY OF PUBLIC HEALTH   (Thailand)

Author keywords

Antiretroviral drugs; GPO VIR; NNRTI based regimen; Resistance; Thailand

Indexed keywords

ABACAVIR; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ADULT; ARTICLE; CD4+ T LYMPHOCYTE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DISEASE DURATION; FEMALE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PHYLOGENY; STATISTICAL SIGNIFICANCE; THAILAND; TREATMENT FAILURE; VIRUS LOAD; VIRUS RESISTANCE; VIRUS TRANSMISSION;

EID: 36549084582     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2007.19.5.528     Document Type: Article

References (35)

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Eng J Med 1998; 338:853-60.
2. Hogg RS, Yip B, Kully C, et al. Improved survival among HIV-infected patients after initiation of triple-drug antiretroviral regimens. CMAJ 1999; 160: 659-65.
3. World Health Oraganization. Progress on global access to HIV antiretroviral therapy. An update on "3 by 5", June, 2005. Geneva: WHO, 2005: 1-34.
4. Blaise P, Clevenbergh P, Vaira D, et al. HIV resistance to antiretroviral drugs: mechanism, genotypic and phenotypic resistance testing in clinical practice. Acta Clin Belg 2002; 57: 191-201.
5. Mallol S. Resistance and other factors involved in therapy failure. Antivir Ther 2001; Suppl. 2: 21-7.
6. Tanuri A, Caridea E, Dantas MC, et al. Prevalence of mutation related to HIV-1 antiretroviral resistance in Brazilian patients failing HAART. J Clin Virol 2002; 25: 39-46.
7. Novak RM, Chen L, Macaethue RD, et al. Prevalence of antiretroviral drug resistance mutations in chronically HIV-infected, treatment-naïve patients: implications for routine resistance screening before initiation of antiretroviral therapy. Clin Infect Dis 2005; 40: 468-74.
8. Bureau of Epidemiology, Department of Diseases Control, Ministry of Public Health, Thailand, 2003.
9. The Thai Working Group on HIV/AIDS projection. Projection for HIV/AIDS in Thailand: 2000-2020. Division of AIDS, Department of Communicable Disease Control, Ministry of Public Health, 2000.
10. Krisintu K. Local resources for global remedies: Increasing access towards a sustainable HIV/AIDS solution, Asia Source, Asia Society, 2001.
11. Krisintu K. Generic production of HIV/AIDS-related drugs in Thailand. In: Improving access to care in developing countries: lesson from practice, research, resources and partnerships. UNAIDS, 2001.
12. Cohen J. Thailand's do-it-yourself therapy. Science 2003; 301:1662.
13. Sirivichayakul S, Ruxrungtham K, Sa-nguansilp C, Phanuphak P. High prevalence of multi-drug resistance mutations in Thai patients treated for prolonged period with double nucleosides. XIV International AIDS conference Barcelona, Spain July 7-12, 2002; TuPeB4605 (Abstr).
14. Chantratita W, Jenwitheesuk E, Watitpun C, et al. Prevalence of HIV-1 polymerase gene mutation in pre-treated patients in Thailand. Southeast Asian J Trop Med Public Health 2002; 33: 80-4.
15. Jenwitheesuk E, Watitpun W, Vibhagool A, et al. Prevalence of genotypic HIV-1 drug resistance in Thailand, 2002. Ann Clin Microbiol Antimicrob 2003; 2:4.
16. Phutanakit T, Sirisanthana V, Sirivichayakul S, et al. Genotypic resistance profiles in HIV-1 reverse transcriptase after 24-week therapy with nevirapine-based HAART in antiretroviral naïve Thai HIV-infected children. In Proceedings of the Fifteenth International AIDS Conference, Bangkok. July 2004 (abstract TuPeB4415).
17. Devereux H, Youle M, Johnson M, Loveday C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999;13:F123-7.
18. Verhofstede C, Wanzeele FV, van der Gucht B, de Cabooter N, Plum J. Interpretation of RTI or a switch from RTI to PI resulted in a fast reappearance of virus strains with a RT-sensitive genotype. AIDS 1999; 13:2541-6.
19. Kuritzkes DR, Grant RM, Feorino P, et al. Performance characteristics of the TRUGENE HIV-1 genotyping kit and the Opengene DNA sequencing system. J Clin Microbiol 2003; 41:1594-9.
20. Visible Genetics. Trugene HIV-1. Toronto, Ontario, Canada: Visible Genetics, 2001; 60.
21. Johnson VA, Brunn-Vezinet F, Clotet B, et al. Update of drug resistance mutation in HIV-1: Fall 2005. Tropical HIV Med 2005;13:125-31.
22. Scott P, Arnold E, Evans B, et al. Surveillance of HIV antiretroviral drug resistance in treated individuals in England: 1998-2000. J Antimicrob Chemother 2004; 53: 469-73.
23. Vergne L, Kane CT, Lauret C, et al. Low rate of genotypic HIV-1 drug-resistant strains in the Senegalese government initiative of access to antiretroviral therapy. AIDS 2003; Suppl 17: s31-8.
24. Casado J, Hertogs K, Luiz R. Non-nucleoside reverse transcriptase inhibitors resistance among patients failing a nevirapine plus protease inhibitors- containing regimen. AIDS 2000; 14: F1-7.
25. Manfredi R. A cross-sectional survey of HIV genotype mutations conferring resistance to all nonnucleoside reverse transcriptase inhibitors and related features, at the time of failure of antiretroviral therapy in the real world. J Acquir Immune Defic Syndr 2001; 28:97-9.
26. Hsiou Y, Ding J, Das K, et al. The Lys 103 Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. J Mol Biol 2001; 309: 437-45.
27. Richman DD, Havlir D, Corbeil J, et al. Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994; 68: 1660-6.
28. Harrigan PR, Hogg RS, Dong WW, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naïve cohort initiating triple antiretroviral therapy. J Infect Dis 2005; 191: 339-47.
29. Beerenwinkel N, Daumer M, Sing T, et al. Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. J Infect Dis 2005; 191: 1953-60.
30. Zhang Z, Hamatake R, Hong Z. Clinical utility of current NNRTIs and perspectives of new agents in this class under development. Antivir Chem Chemother 2004; 15: 121-34.
31. Girouard M, Diallo K, Marchand B, McCormick S, Gotte M. Mutations E44D and V1181 in the reverse transcriptase of HIV-1 play district mechanistic roles in dual resistance to AZT and 3TC. J Biol Chem 2003; 278: 34403-10.
32. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. The M184V mutation reduces the selective excision of zidovudine 5′-monophosphate (AZTMP) by the reverse transcriptase of human immunodeficiency virus type 1. J Virol 2002; 76: 3248-56.
33. Turner D, Brenner BG, Routy JP, Petrella M, Wainberg MA. Rationale for maintenance of the M184V resistance mutation in human immunodeficiency virus type 1 reverse transcriptase in treatment experienced patients. New Microbiol 2004; 27:31-9.
34. Shaffer JP. Multiple Hypothesis testing. Ann. Rev. Psych. 1995; 46: 561-584.
35. Perneger TV. What's wrong with Bonferroni adjustments. Br Med J 1998; 316: 1236-1238.